Hi Cody, Thanks a lot for your reasonable response to my

New Post Public Reply Private Reply Replies (1) Message Board
Zolis_onkel Cody760 #34281
550
Hi Cody,

Thanks a lot for your reasonable response to my post. I am happy to discuss these matters on that basis, which is very different from these "the sky is falling" (a judgement mostly based on negative speculation) posts that I am shaking my head about.
So here is my reply to your post.
1) for sure the situation does not look good, but only because we do not know what is really going on and we do not receive any first hand information from the company officials directly. Agreed.
2) Why do you think that they have been running out of money? If they would have, they would have been giving out shares to keep the lights on, as they did in the summer and fall months. And in case there is no investigation, as some here strongly suggest, what keeps them from doing so? Fact is they don't. This is a fact, because the official otcmarkets website says so.
3) Now why are they not diluting the heck out of the stock? Three possible answers come to my mind:
a) they are actually generating enough revenue from the Excellegen sales, which they had laid out clear plans for during the last CC in May. Capital was about to be secured through debt financing and the strategy was very clearly described. If they have only been 50% successful with the described roll out, as planned, there should millions be rolling in by now every month.
b) they are not allowed to give out new shares due to an investigation that is going on, which restricts them also in communication to the public/us shareholders. This scenario is also supported by the fact that Joe gave hints to some posters and the canned emails some received from Todd, where he said that they are still making progress and all fronts, but he is not able to talk about details right now. How long this will still be so he can't really predict. In addition, based on all of our personal experiences with the company, it is very unusual that they remain in CompleteSilence for such a long time, and thus it is hard for me to believe that they are doing this for any other reason than a gag order.
Question remains if the lack of funding is really limiting them, or do they come along well without additional funding, e.g. due to a)
c) as you suggested, they ran into problems, simply gave up and all just left. I honestly doubt that Joe would do something like that, especially after he had dedicated almost 5 years of his life on this already. And even if that is true, would he actually still be posting trash about other vaccine developers and their products? If I world have given up on such an endeavor, I would not be bothered with this at all anymore, but minding my own business and trying to figure out what to do next in my life. Don't you agree?
4) I do agree with you on your suggestion that Joe and his team "have been overtaken by events beyond their control". I recently read a longer article about the reasons why this pandemic had to happen to save the world's financial systems. Now, of course, this very much sounds like a conspiracy theory, but it was very well written (in German, which is why I am not providing a link here, but whomever is interested, can send me private message and I will send it), and most of the allegations made, were proven via links to official governmental websites, etc. So I can absolutely believe this to be true.

In this described conspiracy it is necessary that a) a vaccine is used that causes a lot of side effects (all of a sudden the choice of that mRNA technology makes sense) and even deaths, and b) that a vast majority of people in western countries are vaccinated (so ever since it is clear to me that our governments will sooner or later make a vaccination mandatory).
Assuming this to be true, the "deep state" conspirists cannot use a CompleteVaccine that has very little side effects and provides long term immunity, which is why GNBT has never received funding from BARDA and a quick refusal from that other "Bill Gates foundation" organization, who clearly stated that they would only support mRNA vaccine developments. After that and Joe's decision to continue anyways, they faced one problem after the next, the FDA requested yet another and another set of tests, in the meantime the pps was being manipulated down and now the company is under investigation for the most part of the last two years. First a deep dive review of their 2019 10-k and now something else.
I know, I know how this sounds, and I am not saying that this is true, but connecting the dots this way, a lot questions (eg. Why has BARDA funded almost solely the development of mRNA vaccine developments, which entirely defies any of my common sense or logic) for me receive answers.

And no, this has nothing to do with defending Joe, or trying to give him an easy way out or absolution. The "bad actors" he has been referring to and used as excuses for his short comings, are still mostly his fault and due to his naivity or lack of proper due diligence etc.

OK, enough said, now hit me with your responses. Hard had and coat of mail are on already. LOL

Generex Biotechnology Corp. (GNBTQ) Stock Research Links

GNBTQ Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

TilePix Expands into Walmart with Nail-Free Decor Launch

Updated Category News Views 11

TilePix Makes Big Moves with Walmart TilePix is launching their new line of nail-free wall décor at Walmart—this ain’t your grandma’s wall art. This company's bringing their magnetic, nail-free wizardry to retail stores nationwide for the first time, and they’ve chosen a real heavyweight partner—Walmart. What comes in the package? Well, they’re dealing in...

Continue Reading
Clean Power Alliance's Bond Deal Secures $91M Savings

Updated Category News Views 12

CPA Triumphs Yet Again With Bond Savings I'll tell you, the Clean Power Alliance (CPA) just hit the jackpot again. We're talking a $1.4 billion energy prepayment bond deal that locks in a whopping $91.1 million in savings over the next seven years. Not bad, huh? A Closer Look at the Numbers CPA's charm—besides being the top green power supplier in the U.S.—is spinning...

Continue Reading
Dickinson Brands Celebrates Witch Hazel Legacy with Event

Updated Category News Views 18

Witch Hazel's Timeless Appeal You don’t get to celebrate over one and a half centuries of a product without doing something right. Dickinson Brands Inc. is throwing a bash worth noticing as they mark the sixth annual National Witch Hazel Day on October 21st. It’s a head-nod to the versatile witch hazel, a product that’s been part of New England's heritage since the...

Continue Reading
Coastal Financial Faces Lawsuit Over Fraud Allegations

Updated Category News Views 7

Coastal Financial Corporation, riding high on NASDAQ as CCB, now finds itself in the middle of a storm. Schall, Brown & Schwartz LLP, a firm known for its shareholder rights litigation, has thrown the gauntlet with a class action lawsuit against Coastal for suspected securities violations. We're talking about potential fibs under Section 10(b) and 20(a) of the Securities...

Continue Reading
D2L Ventures into Vietnam with Van Lang Alliance

Updated Category News Views 12

Unlocking New Frontiers in Vietnam's Education Well, looks like D2L is rolling into Vietnam with the kind of gusto you'd expect from a company that fancies itself a trailblazer in learning tech. This ain't just another humdrum expansion story; it's a five-year handshake with Van Lang Education Group that's got the tech firm dropping its anchor in a fresh and promising...

Continue Reading
Endava Faces Securities Fraud Lawsuit: Investor Implications

Updated Category News Views 6

Endava in Hot Water Over Alleged Misleading Statements Alright, folks, gather around—there's a storm brewing over at Endava with shareholders mightier than the Greek gods, furrowing their brows with intent. You see, Schall, Brown & Schwartz LLP, a firm that practically eats legal challenges for breakfast, is beating the drums of a securities fraud lawsuit. Yep, I'm...

Continue Reading
Firmable's Tech Intelligence: New Edge in B2B Sales

Updated Category News Views 11

New Era for B2B Sales Teams Once again, the B2B sales landscape is getting a jolt—especially for those who’ve been fumbling in the dark pitching to prospects without any real idea of their tech environment. With the introduction of Firmable's Tech Intelligence, those blind days just got a lot brighter. By offering detailed insights into what technologies a company is...

Continue Reading
Roof Inspections: Richmond's Key to Home Longevity

Updated Category News Views 12

Inspect, Protect, and Forget Your Worries Homeowners in the Greater Richmond area wisely take to heart the old saying: an ounce of prevention is worth a pound of cure. But let's cut through the noise for a moment and zero in on a foundational truth: regular roof inspections are not a luxury—they're an absolute must. Roofing expert Seth Brown, from BNH Roofing, makes it...

Continue Reading
Veteran Team Fuels Misunderstood Brands' Bold Expansion

Updated Category News Views 6

Adding Heavyweights to Catalyze Growth Imagine you're Misunderstood Brands, prepping your artillery before charging into the battleground of national chains. What do you do? You double down strategically by rallying the best industry minds around. Announced on October 15, 2026, this company's concocted a dream team of beverage veterans as they steer their products—like...

Continue Reading
AAI Rolls Out Agency Gauge: AI-Driven Insights Platform

Updated Category News Views 13

Bringing Artificial Intelligence to the Insurance Table Affordable American Insurance (AAI) is shaking things up in the insurance world with their new tool, Agency Gauge. Picture this: you're running an independent agency, neck-deep in data, and this AI-powered marvel swoops in and turns those confusing numbers into actionable business insights. It's like having a wise...

Continue Reading

Top 5 Most Recently Viewed Articles

Exodus Movement, Inc. Prepares for Important Financial Reveal

Updated Category News Views 123

Exodus Movement, Inc. Prepares to Share 2024 Financial Results Exodus Movement, Inc. (NYSE American: EXOD) is a prominent name in the world of self-custodial cryptocurrency platforms. Recently, the company announced it will disclose its fourth quarter and full year 2024 financial results on an upcoming date, providing investors with keen insights into their performance....

Continue Reading
Rudy Diaz Steps in as New CEO at Safe Haven Defense Today

Updated Category News Views 289

Rudy Diaz Steps into Role as CEO of Safe Haven Defense Safe Haven Defense US, LLC, known for its innovative window security laminate systems, has appointed Rodolfo "Rudy" Diaz as its new Chief Executive Officer. This important move marks a new chapter for the company, furthering its commitment to excellence in security solutions across North America. Leadership Changes...

Continue Reading
How Beam Global's EV ARC™ Systems Weathered Hurricane Helene

Updated Category News Views 109

Beam Global EV ARC™ Systems Show Resilience in Hurricane Helene In a remarkable display of endurance, Beam Global's EV ARC™ systems remained operational during Hurricane Helene, highlighting their essential role in providing reliable energy solutions in critical situations. As the hurricane slammed into the southeastern United States, Beam Global, a prominent player...

Continue Reading
Simon Dingemans Joins Avantor Board to Foster Growth

Updated Category News Views 136

Avantor Welcomes New Board Member Simon Dingemans Avantor, Inc. (NYSE: AVTR), a prominent global provider of essential products and services to the life sciences sector, has announced a significant addition to its Board of Directors. Simon Dingemans, a seasoned executive with a wealth of experience in various industries, will officially join the board on January 2, 2026....

Continue Reading
Odronextamab's Path to FDA Approval for Lymphoma Treatment

Updated Category News Views 204

Odronextamab BLA Accepted for FDA Review Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) recently announced the FDA's acceptance of the Biologics License Application (BLA) for odronextamab, targeting relapsed or refractory follicular lymphoma (R/R FL) following multiple lines of systemic therapy. The decision by the FDA serves as a significant milestone in the...

Continue Reading